117 related articles for article (PubMed ID: 10684699)
1. Reduction of BRCA1 expression in sporadic ovarian cancer.
Zheng W; Luo F; Lu JJ; Baltayan A; Press MF; Zhang ZF; Pike MC
Gynecol Oncol; 2000 Mar; 76(3):294-300. PubMed ID: 10684699
[TBL] [Abstract][Full Text] [Related]
2. Decreased luteinizing hormone receptor mRNA expression in human ovarian epithelial cancer.
Lu JJ; Zheng Y; Kang X; Yuan JM; Lauchlan SC; Pike MC; Zheng W
Gynecol Oncol; 2000 Nov; 79(2):158-68. PubMed ID: 11063638
[TBL] [Abstract][Full Text] [Related]
3. Ovarian epithelial tumor growth promotion by follicle-stimulating hormone and inhibition of the effect by luteinizing hormone.
Zheng W; Lu JJ; Luo F; Zheng Y; Feng Yj; Felix JC; Lauchlan SC; Pike MC
Gynecol Oncol; 2000 Jan; 76(1):80-8. PubMed ID: 10620446
[TBL] [Abstract][Full Text] [Related]
4. Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene.
Wang C; Horiuchi A; Imai T; Ohira S; Itoh K; Nikaido T; Katsuyama Y; Konishi I
J Pathol; 2004 Feb; 202(2):215-23. PubMed ID: 14743504
[TBL] [Abstract][Full Text] [Related]
5. Imbalanced expression of inhibin and activin subunits in primary epithelial ovarian cancer.
Zheng W; Luo MP; Welt C; Lambert-Messerlian G; Sung CJ; Zhang Z; Ying SY; Schneyer AL; Lauchlan SC; Felix JC
Gynecol Oncol; 1998 Apr; 69(1):23-31. PubMed ID: 9570994
[TBL] [Abstract][Full Text] [Related]
6. Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome.
Brustmann H
Int J Gynecol Pathol; 2007 Apr; 26(2):147-53. PubMed ID: 17413981
[TBL] [Abstract][Full Text] [Related]
7. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
Sakata K; Shigemasa K; Nagai N; Ohama K
Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer.
Chan KY; Ozçelik H; Cheung AN; Ngan HY; Khoo US
Cancer Res; 2002 Jul; 62(14):4151-6. PubMed ID: 12124354
[TBL] [Abstract][Full Text] [Related]
9. Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases.
Yoshikawa K; Honda K; Inamoto T; Shinohara H; Yamauchi A; Suga K; Okuyama T; Shimada T; Kodama H; Noguchi S; Gazdar AF; Yamaoka Y; Takahashi R
Clin Cancer Res; 1999 Jun; 5(6):1249-61. PubMed ID: 10389907
[TBL] [Abstract][Full Text] [Related]
10. Survivin expression in ovarian cancer.
Liguang Z; Peishu L; Hongluan M; Hong J; Rong W; Wachtel MS; Frezza EE
Exp Oncol; 2007 Jun; 29(2):121-5. PubMed ID: 17704744
[TBL] [Abstract][Full Text] [Related]
11. Expression of steroid hormone receptors in BRCA1-associated ovarian carcinomas.
Aghmesheh M; Edwards L; Clarke CL; Byth K; Katzenellenbogen BS; Russell PJ; Friedlander M; Tucker KM; de Fazio A
Gynecol Oncol; 2005 Apr; 97(1):16-25. PubMed ID: 15790432
[TBL] [Abstract][Full Text] [Related]
12. The lysophosphatidic acid (LPA) receptors their expression and significance in epithelial ovarian neoplasms.
Wang P; Wu X; Chen W; Liu J; Wang X
Gynecol Oncol; 2007 Mar; 104(3):714-20. PubMed ID: 17204312
[TBL] [Abstract][Full Text] [Related]
13. Quantitative analysis of follicle-stimulating hormone receptor in ovarian epithelial tumors: a novel approach to explain the field effect of ovarian cancer development in secondary mullerian systems.
Wang J; Lin L; Parkash V; Schwartz PE; Lauchlan SC; Zheng W
Int J Cancer; 2003 Jan; 103(3):328-34. PubMed ID: 12471615
[TBL] [Abstract][Full Text] [Related]
14. Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumors: correlation with Ki-67 and p53 immunoreactivity.
Bar JK; Grelewski P; Popiela A; Noga L; Rabczyñski J
Gynecol Oncol; 2004 Oct; 95(1):23-31. PubMed ID: 15385106
[TBL] [Abstract][Full Text] [Related]
15. Expression of extracellular matrix proteins in ovarian serous tumors.
Salani R; Neuberger I; Kurman RJ; Bristow RE; Chang HW; Wang TL; Shih IeM
Int J Gynecol Pathol; 2007 Apr; 26(2):141-6. PubMed ID: 17413980
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of mammaglobin B in epithelial ovarian carcinomas.
Tassi RA; Bignotti E; Rossi E; Falchetti M; Donzelli C; Calza S; Ravaggi A; Bandiera E; Pecorelli S; Santin AD
Gynecol Oncol; 2007 Jun; 105(3):578-85. PubMed ID: 17343903
[TBL] [Abstract][Full Text] [Related]
17. Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression.
Motamed-Khorasani A; Jurisica I; Letarte M; Shaw PA; Parkes RK; Zhang X; Evangelou A; Rosen B; Murphy KJ; Brown TJ
Oncogene; 2007 Jan; 26(2):198-214. PubMed ID: 16832351
[TBL] [Abstract][Full Text] [Related]
18. [Protein and mRNA expression of aquaporin-1 in epithelial ovarian tumors and its clinic significance].
Yang JH; Shi YF; Cheng Q; Qian YL
Zhonghua Fu Chan Ke Za Zhi; 2005 Sep; 40(9):623-6. PubMed ID: 16202320
[TBL] [Abstract][Full Text] [Related]
19. Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival.
Rosen DG; Wang L; Jain AN; Lu KH; Luo RZ; Yu Y; Liu J; Bast RC
Clin Cancer Res; 2004 Oct; 10(19):6559-66. PubMed ID: 15475444
[TBL] [Abstract][Full Text] [Related]
20. Level of Id-1 protein expression correlates with poor differentiation, enhanced malignant potential, and more aggressive clinical behavior of epithelial ovarian tumors.
Schindl M; Schoppmann SF; Ströbel T; Heinzl H; Leisser C; Horvat R; Birner P
Clin Cancer Res; 2003 Feb; 9(2):779-85. PubMed ID: 12576450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
